# A Study to Evaluate the Drug Levels, Metabolism and Excretion, and Absolute Bioavailability of BMS-986365 in Healthy Male Participants

> **NCT06433505** · PHASE1 · COMPLETED · sponsor: **Celgene** · enrollment: 24 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** BMS-986365
- **DRUG:** [14C] BMS-986365
- **DRUG:** [14C] BMS-986409 + BMS-986410
- **DRUG:** [14C] BMS-986410 + BMS-986409

## Key facts

- **NCT ID:** NCT06433505
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-05-30
- **Primary completion:** 2025-02-14
- **Final completion:** 2025-02-28
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2025-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06433505

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06433505, "A Study to Evaluate the Drug Levels, Metabolism and Excretion, and Absolute Bioavailability of BMS-986365 in Healthy Male Participants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06433505. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*